Mangoceuticals, Common Other Operating Expenses Over Time
| MGRX Stock | 2.50 0.03 1.19% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Mangoceuticals, Common Performance and Mangoceuticals, Common Correlation. Mangoceuticals, |
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mangoceuticals, Common. If investors know Mangoceuticals, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mangoceuticals, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.70) | Revenue Per Share 0.615 | Quarterly Revenue Growth 0.155 | Return On Assets (0.58) | Return On Equity (1.08) |
The market value of Mangoceuticals, Common is measured differently than its book value, which is the value of Mangoceuticals, that is recorded on the company's balance sheet. Investors also form their own opinion of Mangoceuticals, Common's value that differs from its market value or its book value, called intrinsic value, which is Mangoceuticals, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mangoceuticals, Common's market value can be influenced by many factors that don't directly affect Mangoceuticals, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mangoceuticals, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mangoceuticals, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mangoceuticals, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Other Operating Expenses Analysis
Compare Mangoceuticals, Common and related stocks such as Profound Medical Corp, Si Bone, and Nevro Corp Other Operating Expenses Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PROF | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 8.1 M | 11.6 M | 17.9 M | 16.7 M | 19.4 M | 26.2 M | 37.2 M | 36.3 M | 35.8 M | 23.5 M |
| SIBN | 47.7 M | 47.7 M | 47.7 M | 54.2 M | 66.3 M | 67.7 M | 59.7 M | 65.3 M | 67.3 M | 103.3 M | 112 M | 141.8 M | 166 M | 185.8 M | 104.2 M |
| NVRO | 37.3 M | 37.3 M | 37.3 M | 48.7 M | 60.9 M | 132 M | 251.6 M | 356.3 M | 429 M | 486.7 M | 424.9 M | 477.8 M | 505.2 M | 524.5 M | 342.4 M |
| FNA | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 103.6 M | 108.9 M | 158.2 M | 216.4 M | 253.7 M | 185 M |
| KIDS | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 30.8 M | 37.6 M | 43.4 M | 52.1 M | 67.1 M | 81.6 M | 91.5 M | 115.9 M | 144.1 M | 174.5 M | 92.3 M |
| OFIX | 19.7 M | 490 M | 371.3 M | 373.5 M | 369.5 M | 378.2 M | 372.3 M | 395.5 M | 419.9 M | 444.5 M | 413.3 M | 455.2 M | 481.4 M | 885.8 M | 930 M |
| NPCE | 59 M | 59 M | 59 M | 59 M | 59 M | 59 M | 59 M | 59 M | 59 M | 59 M | 54.2 M | 68.9 M | 86.3 M | 92.6 M | 79.4 M |
| BVS | 240.4 M | 240.4 M | 240.4 M | 240.4 M | 240.1 M | 248.1 M | 291.8 M | 291.8 M | 291.8 M | 308.4 M | 299.4 M | 409.8 M | 560.7 M | 594.1 M | 390.2 M |
Mangoceuticals, Common and related stocks such as Profound Medical Corp, Si Bone, and Nevro Corp Other Operating Expenses description
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Mangoceuticals, Common. It is also known as Mangoceuticals, Common overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.My Equities
My Current Equities and Potential Positions
| Mangoceuticals, Common Stock | MGRX |
Specialization | Health Care, Health Care Equipment & Services |
| Location | Texas; U.S.A |
| Exchange | NASDAQ Exchange |
null 2.5
Additional Tools for Mangoceuticals, Stock Analysis
When running Mangoceuticals, Common's price analysis, check to measure Mangoceuticals, Common's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Mangoceuticals, Common is operating at the current time. Most of Mangoceuticals, Common's value examination focuses on studying past and present price action to predict the probability of Mangoceuticals, Common's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Mangoceuticals, Common's price. Additionally, you may evaluate how the addition of Mangoceuticals, Common to your portfolios can decrease your overall portfolio volatility.